• EuroMed (Northvale, New Jersey) has added a new product to its SureSkin line of hydrocolloid dressings, launching what it called "a new offensive against chronic and acute wounds." The new product is called SureSkin III Silver because it is constructed with silver ions that serve as antimicrobial agents throughout the entire wear time of the dressing. The silver ions in the SurSkin III Silver dressing attack bacteria by way of their cell walls. The dead bacteria are then absorbed into the wound dressing gel and are removed when the dressing is changed, along with moderate levels of wound exudates. Hydrocolloid dressings create a moist wound environment that facilitates the healing process. EuroMed makes wound-care management products.

• HoMedics (Commerce Township, Michigan) reported that its Thera-P Blood Pressure Monitors are compatible with Microsoft HealthVault, a free Web-based platform designed to put consumers in control of their health data. HoMedics blood pressure units, with HealthVault, incorporate features including DK Technology, which uses a built-in microphone to listen to the body to take an accurate reading. HoMedics makes personal healthcare and wellness products.

• Nephros (New York) said it has completed the U.S. clinical trial for its OLpur H2H module and OLpur MD220 filter for end stage renal disease (ESRD) therapy. The Nephros line of water-filtration products incorporates its patented cold sterilization filtration technology, the Dual Stage Ultrafilter (DSU). The DSU has the capability to filter out bacteria, parasites, viruses and other biotoxins to produce biologically safe water, and its dual-stage design reduces the risk and facilitates detection of filter failure. With initial applications targeted at infection-control and potable water solutions, the DSU is in a pilot-use program at a U.S. medical center and has been selected for further development by the U.S. Marine Corps. Nephros makes products for ESRD therapy and water ultrafiltration.

• Omnicell (Seattle) reported general availability of both its SinglePointe automated patient-specific management solution and Omnicell 12.0 automated dispensing software. Both solutions have been successfully implemented at a number of healthcare facilities to help pharmacists and nurses to reduce the risk of medication errors and increase staff efficiency. Randall Lipps, chairman/president/CEO of Omnicell, said, "The SinglePointe solution represents a major leap forward in medication management by providing a single point of access and a way to store, manage and track patient-specific medications. We have also incorporated many new features in Omnicell 12.0 that were inspired by feedback from our customers and designed to help medical staff to reduce medications errors." Omnicell makes products for acute healthcare facilities.

• Respironics (Murrysville, Pennsylvania) reported the release of the Alice LE sleep system. The device is intended to help sleep technicians use the most appropriate system when performing routine polysomnogram studies. It has 31 channels and is the size of the current Respironics Alice 5 sleep system. The Alice LE runs on the Sleepware software program that is designed to monitor, display, process and download polysomnographic data. Respironics makes products for the sleep and respiratory markets.

• Sequenom (San Diego) reported positive results from screening studies using the company's noninvasive circulating cell-free fetal (ccff) nucleic acid SEQureDx technology, which enables the detection of fetal aneuploidy, including Down syndrome from maternal blood. Sequenom's SEQureDx technology is a novel approach to genetic screening. Unlike current standards of harvesting placental tissue cells as is required for chorionic villus, or entering the uterus to sample the amniotic fluid surrounding the baby as is performed with amniocentesis, SEQureDx extracts fetal nucleic acid material safely and comfortably from a simple blood specimen collected from the mother to determine the genetic status of the fetus. This suggests that effective screening may be accomplished in the future without the risks associated with disturbing the amniotic fluid that surrounds the baby in the uterus. Sequenom makes genetic-analysis products for research and the molecular diagnostics market.

• Soquel Group (Monterey, California) has introduced a new tool, the Shark Tooth Starter Broach, for performing minimally invasive hip replacement surgery. Measuring approximately 6 cm in length, the Shark Tooth is a much smaller broach than currently available in the toolkits provided with hip replacement systems. The Shark Tooth helps surgeons to more easily prepare the femur for joint implants through a smaller incision. The design of the new broach allows proper orientation of the broach when limited by the constraints of the anatomy of the anterior approach or when spatial constraints pose a problem. Soquel Group provides strategic services to innovative technology companies including patent drafting, prosecution, and commercialization.